The DOI matches its Crossref record.
Phenotypic and Functional Analysis of Dendritic Cells and Clinical Outcome in Patients With High-Risk Melanoma Treated With Adjuvant Granulocyte Macrophage Colony-Stimulating Factor
Abstract
Purpose: Granulocyte macrophage colony-stimulating factor (GM-CSF) can induce differentiation of dendritic cells (DCs) in preclinical models. We hypothesized that GM-CSF–stimulated DC differentiation may result in clinical benefit in patients with high-risk melanoma. Patients and Methods: We conducted a prospective trial in patients with high-risk (stage III B/C, IV), resected melanoma, with GM-CSF 125 μg/m 2/d administered for 14 days every 28 days. Patients underwent clinical restaging every four cycles, with DC analysis performed at baseline and at 2, 4, 8, and 12 weeks. Results: Of 42 patients enrolled, 39 were assessable for clinical outcome and DC analysis. Median overall survival was 65 months (95% CI, 43 to 67 months) and recurrence-free survival was 5.6 months (95% CI, 3 to 11 months). GM-CSF treatment caused an increase in mature DCs, first identified after 2 weeks of treatment, normalizing by 4 weeks. Patients with decreased DCs at baseline had significant increases in DC number and function compared with those with “normal” parameters at baseline. No change was observed in the number of myeloid-derived suppressor cells (MDSCs). Early recurrence (< 90 days) correlated with a decreased effect of GM-CSF on host DCs, compared with late or no (evidence of) recurrence. Conclusion: GM-CSF treatment was associated with a transient increase in mature DCs, but not MDSCs. Greater increase of DCs was associated with remission or delayed recurrence. The prolonged overall survival observed warrants further exploration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 26
- Cairo MS: Review of G-CSF and GM-CSF: Effects on neonatal neutrophil kinetics. Am J Pediatr Hematol Oncol 11:238,1989-244,
- 10.1200/JCO.2000.18.8.1614 · doi:10.1200/jco.2000.18.8.1614
- 10.1517/14712598.5.3.293 · DOI
- 10.1038/sj.cr.7310017 · DOI · Paper page
- 10.1038/nri1498 · DOI · Paper page
- 10.1158/0008-5472.CAN-06-1690 · DOI · Paper page
- 10.1038/sj.onc.1206459 · DOI · Paper page
- 10.1097/00002371-199903000-00008 · doi:10.1097/00002371-199903000-00008
- 10.1007/s10875-006-9033-3 · doi:10.1007/s10875-006-9033-3
- 10.1093/annonc/mdl158 · DOI · Paper page
- Morton D: Results of multicenter randomized phase III trial of Canvaxin versus BCG in patients with resected stage III or stage IV melanoma. Presented at the 59th Annual Cancer Symposium of the Society for Surgical Oncology , San Diego, CA, March 23-26, 2006
- 10.1200/JCO.2000.18.8.1603 · doi:10.1200/jco.2000.18.8.1603
- 10.1177/107327480501200403 · DOI
- 10.1200/JCO.2002.01.151 · doi:10.1200/jco.2002.01.151
- 10.1200/JCO.2001.19.16.3635 · DOI · Paper page
- 10.1177/107327480601300309 · doi:10.1177/107327480601300309
- 10.1002/cncr.21835 · DOI
- 10.1200/JCO.1998.16.3.1103 · DOI · Paper page
- 10.1177/107327480601300308 · DOI
- 10.1080/08820130600803429 · DOI · Paper page
- 10.1158/1078-0432.CCR-07-0409 · DOI · Paper page
- 10.4049/jimmunol.166.1.678 · DOI · Paper page
- 10.1158/0008-5472.CAN-04-0757 · DOI · Paper page
- 10.1016/S0959-8049(03)00131-X · doi:10.1016/s0959-8049(03)00131-x
- 10.1200/JCO.2006.08.5829 · DOI · Paper page
- 10.1016/S0305-7372(03)00074-4 · DOI · Paper page
Cited by
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Self-citationTherapeutic Targeting of the Tumor Microenvironment
Bejarano, L., Jordāo, M. J. C., & Joyce, J. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1808 · Cited by 1,653
Systemic effects of local radiotherapy
Formenti, S. C., & Demaria, S. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70082-8 · Cited by 1,021
Electroporation-Based Technologies for Medicine: Principles, Applications, and Challenges
Yarmush, M. L., Golberg, A., Serša, G., Kotnik, T., & Miklavčič, D. (2014) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071813-104622 · Cited by 889
T Helper 17 Cells Promote Cytotoxic T Cell Activation in Tumor Immunity
Martin-Orozco, N., Muranski, P., Chung, Y., Yang, X. O., Yamazaki, T., Lu, S., Hwu, P., Restifo, N. P., Overwijk, W. W., & Dong, C. (2009) · Immunity · doi:10.1016/j.immuni.2009.09.014 · Cited by 800
Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF V600E melanoma
Hu-Lieskovan, S., Mok, S., Homet Moreno, B., Tsoi, J., Robert, L., Goedert, L., Pinheiro, E. M., Koya, R. C., Graeber, T. G., Comin-Anduix, B., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4691 · Cited by 563
Cancer Immunotherapy by Dendritic Cells
Melief, C. J. M. (2008) · Immunity · doi:10.1016/j.immuni.2008.08.004 · Cited by 508
Myeloid derived suppressor cells in human diseases
Greten, T. F., Manns, M. P., & Korangy, F. (2011) · International Immunopharmacology · doi:10.1016/j.intimp.2011.01.003 · Cited by 398
Görgün, G. T., Whitehill, G., Anderson, J. L., Hideshima, T., Maguire, C., Laubach, J., Raje, N., Munshi, N. C., Richardson, P. G., & Anderson, K. C. (2013) · Blood · doi:10.1182/blood-2012-08-448548 · Cited by 393
Poschke, I., Mougiakakos, D., Hansson, J., Masucci, G. V., & Kiessling, R. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3767 · Cited by 382
Dumitru, C. A., Moses, K., Trellakis, S., Lang, S., & Brandau, S. (2012) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-012-1294-5 · Cited by 374
Technologies for enhanced efficacy of DNA vaccines
Saade, F., & Petrovsky, N. (2012) · Expert Review of Vaccines · doi:10.1586/erv.11.188 · Cited by 309
Difference in Membrane Repair Capacity Between Cancer Cell Lines and a Normal Cell Line
Frandsen, S. K., McNeil, A. K., Novak, I., McNeil, P. L., & Gehl, J. (2016) · The Journal of Membrane Biology · doi:10.1007/s00232-016-9910-5 · Cited by 53
Metadata
- Authors
- Daud, A. I., Mirza, N., Lenox, B., Andrews, S., Urbas, P., Gao, G. X., Lee, J.-H., Sondak, V. K., Riker, A. I., DeConti, R. C., & Gabrilovich, D.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-07-01
- Volume
- 26
- Issue
- 19
- Pages
- 3235-3241
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2117933504
- Cited by
- 184
- References
- 0
- FWCI
- 7.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.